Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | PYGL | P06737 | 13/20 | 0.34 |
| ▸ | PYGM | P11217 | 10/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119152 | 0.84 | GAA (0.38) | ESR2ESR1PYGLPYGM | |
| SCHEMBL23119153 | 0.75 | NPY1R (0.45) | — | |
| SCHEMBL14193208 | 0.73 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL7419284 | 0.72 | AADAT (0.40) | PYGLPYGM | |
| SCHEMBL7423564 | 0.72 | KYAT1 (0.46) | PYGLPYGM | |
| SCHEMBL9974770 | 0.70 | LIPG (0.39) | PYGLPYGM | |
| SCHEMBL4800991 | 0.68 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL4800980 | 0.68 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL4799822 | 0.68 | MTNR1A (0.49) | PYGLPYGM | |
| SCHEMBL4799807 | 0.68 | MTNR1A (0.49) | PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ESR2 2695/4885ESR1 2683/4885PYGL 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.